Patents Examined by Tamthom N. Truong
-
Patent number: 7625908Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.Type: GrantFiled: November 11, 2004Date of Patent: December 1, 2009Assignee: AstraZeneca ABInventors: Laurent Francois Andre Hennequin, Robert Hugh Bradbury, Jason Grant Kettle
-
Patent number: 7625909Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.Type: GrantFiled: May 21, 2004Date of Patent: December 1, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher R. Conlee, Brian D. Thompson, Judith de Armas Kuntz, David L. Musso, Kevin K. Barvian, Stephen A. Thomson, William R. Swain, Kien S. Du, Brian A. Chauder, Jason D. Speake, Michael J. Bishop
-
Patent number: 7625911Abstract: The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.Type: GrantFiled: January 12, 2005Date of Patent: December 1, 2009Assignee: Mai De Ltd.Inventor: Le Huang
-
Patent number: 7615554Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.Type: GrantFiled: January 25, 2006Date of Patent: November 10, 2009Assignees: Prolexys Pharmaceuticals, Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New YorkInventors: Robert Selliah, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Brent R. Stockwell, Raj Gopal Venkat
-
Patent number: 7605165Abstract: The present invention relates to the following phenylalanine derivatives or analogues thereof having an antagonistic activity to ?4 integrin and therapeutic agents for various diseases concerning ?4 integrin.Type: GrantFiled: August 20, 2004Date of Patent: October 20, 2009Assignee: Ajinomoto Co., Inc.Inventors: Kazuyuki Sagi, Hiroyuki Izawa, Akira Chiba, Tatsuya Okuzumi, Toshihiko Yoshimura, Yuji Tanaka, Miho Ono, Masahiro Murata
-
Patent number: 7598383Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specifications. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.Type: GrantFiled: November 18, 2004Date of Patent: October 6, 2009Assignee: Array Biopharma Inc.Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
-
Patent number: 7589098Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.Type: GrantFiled: March 21, 2005Date of Patent: September 15, 2009Assignee: Cytokinetics, Inc.Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
-
Patent number: 7585869Abstract: The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R11, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: May 20, 2004Date of Patent: September 8, 2009Assignee: Pfizer, Inc.Inventors: Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
-
Patent number: 7582631Abstract: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.Type: GrantFiled: January 11, 2005Date of Patent: September 1, 2009Assignee: Amgen Inc.Inventors: Celia Dominguez, Anthony Reed, Kelvin K. C. Sham, Maya C. Thaman
-
Patent number: 7582665Abstract: Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X1—Y1-Z1-W1??(I) wherein X1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y1 is —NRACO—(CH2)0-2— or the like (wherein RA is a hydrogen or the like); Z1 is optionally substituted phenylene or the like; and W1 is a group represeted by the below formula: wherein R1, R2, R3, and R4 are each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line ( - - - ) represents the presence or absence of bond.Type: GrantFiled: January 23, 2001Date of Patent: September 1, 2009Assignee: Shionogi & Co., Ltd.Inventors: Hiroshi Takemoto, Takeshi Shiota, Masami Takayama
-
Patent number: 7569577Abstract: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.Type: GrantFiled: September 13, 2004Date of Patent: August 4, 2009Assignee: Astrazeneca ABInventors: Laurent Francois Andre Hennequin, Christopher Thomas Halsall
-
Patent number: 7569564Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.Type: GrantFiled: February 9, 2006Date of Patent: August 4, 2009Assignee: WyethInventors: Puwen Zhang, Andrew Fensome, Eugene A. Terefenko, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Jay E. Wrobel, Mark A. Collins
-
Patent number: 7569578Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.Type: GrantFiled: December 3, 2004Date of Patent: August 4, 2009Assignee: Bristol-Meyers Squibb CompanyInventors: Guanglin Luo, Ling Chen, Andrew P. Degnan, Gene M. Dubowchik, John E. Macor, George O. Tora, Prasad V. Chaturvedula
-
Patent number: 7560461Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.Type: GrantFiled: August 22, 2005Date of Patent: July 14, 2009Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 7557115Abstract: Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.Type: GrantFiled: September 30, 2003Date of Patent: July 7, 2009Assignee: Cytokinetics, Inc.Inventors: Gustave Bergnes, David J. Morgans, Jr.
-
Patent number: 7547709Abstract: Compounds, preferably 5-pyrimidinol and 3-pyridinol derivatives, that act as effective chain breaking antioxidants of both the lipid and water-soluble variety (analogous to the natural Vitamins E and C), many of which are more reactive toward peroxyl radicals than the most potent form of Vitamin E. These compounds may exhibit many chemopreventive effects associated with conditions in which free radical-mediated cellular damage or disruption is implicated and Vitamins E and C are shown to have protective effects. Additionally, these compounds should be excellent oxidation inhibitors as additives to fuels, lubricants, rubber, polymers, chemicals, solvents and foodstuffs.Type: GrantFiled: November 2, 2004Date of Patent: June 16, 2009Assignee: Vanderbilt UniversityInventors: Derek A. Pratt, Luca Valgimigli, Gino A. DiLabio
-
Patent number: 7547702Abstract: Quinazolines of the formula (I) in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein 1bIX antagonists.Type: GrantFiled: September 17, 2001Date of Patent: June 16, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Werner Mederski, Maria Devant, legal representative, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R. Player, Edward Jaegar, Richard Soll, Ralf Devant
-
Patent number: 7528121Abstract: Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.Type: GrantFiled: December 22, 2003Date of Patent: May 5, 2009Assignee: AstraZeneca ABInventors: Nicola Murdoch Heron, Andrew Austen Mortlock
-
Patent number: 7521456Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.Type: GrantFiled: November 17, 2003Date of Patent: April 21, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
-
Patent number: 7521455Abstract: The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X1 is a nitrogen atom, sulfur atom or oxygen atom, R1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R2 and R3 are amino groups or alkylamino groups, and X2 is represented by formula (II): (where R4 and R5 are lower alkyl groups, and n is an integer from 2 to 4).Type: GrantFiled: February 14, 2005Date of Patent: April 21, 2009Assignee: Banyu Pharmaceutical Co. Ltd.Inventors: Tsuyoshi Nagase, Nagaaki Sato, Akio Kanatani, Shigeru Tokita